Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Model‐informed drug development (MIDD) was central to the development of the oral proteasome inhibitor ixazomib, facilitating internal decisions (switch from body surface area (BSA)‐based to fixed dosing, inclusive phase III trials, portfolio prioritization of ixazomib‐based combinations, phase III...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Pharmacol Ther
Main Authors: Gupta, Neeraj, Hanley, Michael J., Diderichsen, Paul M., Yang, Huyuan, Ke, Alice, Teng, Zhaoyang, Labotka, Richard, Berg, Deborah, Patel, Chirag, Liu, Guohui, van de Velde, Helgi, Venkatakrishnan, Karthik
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Reviews
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585617/
https://ncbi.nlm.nih.gov/pubmed/29446068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1047
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados